CERC is proud to share that TARGET FIRST and SELUTION DeNovo, both conducted with CERC, have been selected among the Top 10 studies in interventional cardiology in 2025 by the European Heart Journal.
CERC is proud to share that TARGET FIRST and SELUTION DeNovo, both conducted with CERC, have been selected among the Top 10 studiesin interventional cardiology in the 2025 European Heart Journal viewpoint reviewing the most influential studies of the year.
The review highlights studies that have significantly shaped interventional cardiology practice, based on methodological rigor, innovation, and expected impact on future guidelines.
TARGET FIRST is recognized for its contribution to simplifying antiplatelet therapy after PCI, demonstrating that early aspirin withdrawal in selected post myocardial infarction patients can reduce bleeding risk without increasing ischemic events.
SELUTION DeNovo is acknowledged as a pivotal study supporting drug coated balloon strategies, showing non-inferiority compared with drug eluting stents in de novo coronary artery lesions and reinforcing the potential of leave nothing behind approaches in a broader patient population.
This double recognition reflects the strong scientific collaboration between sponsors, investigators, and CERC teams, and underlines CERC’s commitment to generating high impact clinical evidence in cardiovascular medicine.
CERC. Smart trials. Strong results.
Read the full article: year in cardiovascular medicine 2025: the top 10 papers in interventional cardiology | European Heart Journal | Oxford Academic
